According to PTC Therapeutics 's latest financial reports the company's current revenue (TTM) is $0.93 B. In 2022 the company made a revenue of $0.69 B an increase over the years 2021 revenue that were of $0.53 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.93 B | 34.2% |
2022 | $0.69 B | 29.75% |
2021 | $0.53 B | 41.45% |
2020 | $0.38 B | 24.04% |
2019 | $0.30 B | 15.96% |
2018 | $0.26 B | 36.19% |
2017 | $0.19 B | 135.04% |
2016 | $82.7 M | 110.72% |
2015 | $39.24 M | 70.92% |
2014 | $22.96 M | -26.69% |
2013 | $31.32 M | 8.85% |
2012 | $28.77 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Novartis NVS | $51.01 B | 5,339.41% | ๐จ๐ญ Switzerland |
Vertex Pharmaceuticals VRTX | $9.86 B | 952.35% | ๐บ๐ธ USA |
Xencor XNCR | $0.16 B | -82.05% | ๐บ๐ธ USA |
Sarepta Therapeutics
SRPT | $1.24 B | 32.58% | ๐บ๐ธ USA |
Fate Therapeutics
FATE | $63.53 M | -93.23% | ๐บ๐ธ USA |
Avidity Biosciences RNA | $9.56 M | -98.98% | ๐บ๐ธ USA |